However, in mice, emerging evidence suggests that ActRIIA/IIB blockade may disrupt glucose homeostasis, given that hepatic follistatin production caused glucose intolerance [26] and Bimagrumab treatment elevated baseline blood glucose levels [16]. Here, ACVR2A is linked to Glucose intolerance.